Loading clinical trials...
Loading clinical trials...
Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients Who Received Capecitabine and Concurrent Intensity Modulated Radiotherapy (IMRT)
Conditions
Interventions
capecitabine and concurrent intensity modulated radiotherapy
Locations
1
China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Start Date
January 1, 2012
Primary Completion Date
January 1, 2017
Completion Date
January 1, 2017
Last Updated
January 9, 2017
NCT06696768
NCT04929028
NCT04704661
NCT05489211
NCT04657068
NCT04674267
Lead Sponsor
General Hospital of Ningxia Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions